A Study Comparing the Closed Triple Therapy, Open Triple Therapy and a Dual Therapy for Effect on Lung Function in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT02731846 | Withdrawn Phase 3

• 1 other identifier: 205165
• Study Type: interventional
• Target: N/A
• Locations: 2 countries
• Sites: 11

Brief Summary

The primary purpose of this study is to assess the equivalence of closed triple therapy Fluticasone Furoate (FF)/Umeclidinium (UMEC)/Vilanterol (VI) to open triple therapy (FF/VI + UMEC), with a comparison of both triple therapies to dual therapy (FF/VI) on lung function. This is a phase III, 4-week, randomized, double-blind, parallel group, multicenter study comparing FF/UMEC/VI (100 micrograms \[mcg\]/62.5 mcg/25 mcg) delivered via a single ELLIPTA® inhaler ('closed' triple) + matching placebo ELLIPTA inhaler, FF/VI + UMEC delivered via two ELLIPTA inhalers ('open' triple) and FF/VI via a single ELLIPTA inhaler + matching placebo ELLIPTA inhaler, all once daily. The total duration of subject participation will be approximately 7 weeks, consisting of a 2-week run-in period, 4-week treatment period and a 1-week follow-up period. ELLIPTA is a registered trade mark of the GSK group of companies.

Conditions

Pulmonary Disease, Chronic Obstructive

Keywords

Efficacy; Triple therapy; Parallel; Respiratory

Outcome Measures

Primary Outcomes (1)

• Change from baseline in trough forced expiratory volume in one second (FEV1) on Day 29

  Forced Expiratory Volume (FEV1) is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second

  Up to Day 29

Secondary Outcomes (4)

• Change from baseline in trough FEV1 on Day 2 and Day 28

  Up to Day 28

• Change from baseline in trough FEV1 on Days 2, 28 and 29

  Up to Day 29

• Change from baseline in weighted mean (WM) FEV1 0-6 hours on Day 1 and Day 28 (in a subset)

  Up to Day 28

• Serial FEV1 over 0-6 hours on Day 1 and Day 28 (in a subset)

  Up to Day 28

Study Arms (3)

FF/UMEC/VI (100/62.5/25 mcg) + placebo

EXPERIMENTAL

Subjects will receive FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg delivered via single ELLIPTA inhaler ('closed' triple) and matching placebo via ELLIPTA inhaler once daily in the morning for 4 weeks as per the randomization. Albuterol/salbutamol will be used as rescue medication throughout the study as needed.

Drug: Fluticasone furoate 100 mcg + Umeclidinium 62.5 mcg+Vilanterol 25 mcg; Drug: Fluticasone furoate 100 mcg + Vilanterol 25 mcg; Drug: Umeclidinium 62.5 mcg; Device: Placebo ELLIPTA inhaler; Drug: Albuterol/Salbutamol

FF/VI 100 mcg/25 mcg + UMEC 62.5 mcg

EXPERIMENTAL

Subjects will receive FF/VI (100 mcg/25 mcg) and UMEC 62.5 mcg delivered via two ELLIPTA inhaler ('open' triple) once daily in the morning for 4 weeks as per the randomization. Albuterol/salbutamol will be used as rescue medication throughout the study as needed.

Drug: Fluticasone furoate 100 mcg + Umeclidinium 62.5 mcg+Vilanterol 25 mcg; Drug: Fluticasone furoate 100 mcg + Vilanterol 25 mcg; Drug: Umeclidinium 62.5 mcg; Drug: Albuterol/Salbutamol

FF/VI 100 mcg/25 mcg + placebo

EXPERIMENTAL

Subjects will receive FF/ VI (100 mcg/25 mcg) delivered via single ELLIPTA inhaler and matching placebo via ELLIPTA inhaler once daily in the morning for 4 weeks as per the randomization. Albuterol/salbutamol will be used as rescue medication throughout the study as needed.

Drug: Fluticasone furoate 100 mcg + Vilanterol 25 mcg; Device: Placebo ELLIPTA inhaler; Drug: Albuterol/Salbutamol

Interventions

Fluticasone furoate 100 mcg + Umeclidinium 62.5 mcg+Vilanterol 25 mcg DRUG

Dry white powder delivered via ELLIPTA inhaler(2 strips with 30 blisters each, first containing fluticasone furoate 100 mcg per blister and second containing Umeclidinium 62.5 mcg and Vilanterol 25 mcg per blister), administered as one inhalation of FF/UMEC/VI (100/62.5/25 mcg) once-daily in the morning

FF/UMEC/VI (100/62.5/25 mcg) + placebo; FF/VI 100 mcg/25 mcg + UMEC 62.5 mcg

Fluticasone furoate 100 mcg + Vilanterol 25 mcg DRUG

Dry white powder delivered via ELLIPTA inhaler (2 strips with 30 blisters each, first containing fluticasone furoate 100 mcg per blister and second containing Vilanterol 25 mcg per blister), administered as one inhalation of FF/VI (100/25 mcg) once-daily in the morning

FF/UMEC/VI (100/62.5/25 mcg) + placebo; FF/VI 100 mcg/25 mcg + UMEC 62.5 mcg; FF/VI 100 mcg/25 mcg + placebo

Umeclidinium 62.5 mcg DRUG

Dry white powder delivered via ELLIPTA inhaler (1 strip with 30 blisters containing Umeclidinium 62.5 mcg, administered as one inhalation once-daily in the morning

FF/UMEC/VI (100/62.5/25 mcg) + placebo; FF/VI 100 mcg/25 mcg + UMEC 62.5 mcg

Placebo ELLIPTA inhaler DEVICE

Placebo will be administered via ELLIPTA inhaler. Dry white powder administered as one inhalation each morning (1 strip with 30 blisters containing placebo)

FF/UMEC/VI (100/62.5/25 mcg) + placebo; FF/VI 100 mcg/25 mcg + placebo

Albuterol/Salbutamol DRUG

Albuterol/salbutamol will be administered via metered-dose inhaler (MDI) with a spacer as needed throughout the study as a rescue medication

FF/UMEC/VI (100/62.5/25 mcg) + placebo; FF/VI 100 mcg/25 mcg + UMEC 62.5 mcg; FF/VI 100 mcg/25 mcg + placebo

Eligibility Criteria

• Age: 40 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• A signed and dated written informed consent prior to study participation.
• Outpatient
• Subjects 40 years of age or older at Screening (V1).
• Male or female subjects.
• A female subject is eligible to participate if she is not pregnant (as confirmed by a negative urine human chorionic gonadotrophin \[hCG\] test), not lactating, and at least one of the following conditions applies:
• Non-reproductive potential as defined in the protocol
• Reproductive potential and agrees to follow methods specified in the protocol for avoiding pregnancy in Females of Reproductive Potential (FRP), from 30 days prior to the first dose of study treatment and until after the last dose of study treatment and completion of the follow-up visit.
• An established clinical history of COPD in accordance with the definition by the American Thoracic Society/European Respiratory Society
• Current or former cigarette smokers with a history of cigarette smoking of \>=10 pack-years at Screening \[number of pack years = (number of cigarettes per day / 20) x number of years smoked (e.g., 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years)\]. Previous smokers are defined as those who have stopped smoking for at least 6 months prior to Screening (V1).
• A score of \>=10 on the COPD Assessment Test (CAT) at Screening (V1).
• A post-albuterol/salbutamol FEV1/ forced vital capacity (FVC) ratio of \<0.70 and a post-albuterol/salbutamol FEV1 of =\<70 percent of predicted normal values at Screening (V1).

You may not qualify if:

• Women who are pregnant or lactating or are planning on becoming pregnant during the study.
• Subjects with a current diagnosis of asthma. (Subjects with a prior history of asthma are eligible if they have a current diagnosis of COPD, which is the primary cause of their respiratory symptoms).
• Subjects with alpha-1-antitrypsin deficiency as the underlying cause of COPD.
• Subjects with active tuberculosis are excluded. Subjects with other respiratory disorders (e.g. clinically significant: bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, interstitial lung diseases) are excluded if these conditions are the primary cause of their respiratory symptoms.
• Subjects with lung volume reduction surgery (including procedures such as endobronchial valves) within the 12 months prior to Screening (V1).
• Immune suppression (e.g. advanced Human Immunodeficiency Virus (HIV) with high viral load and low CD4 count, Lupus on immunosuppressants that would increase risk of pneumonia) or other risk factors for pneumonia (e.g. neurological disorders affecting control of the upper airway, such as Parkinson's Disease, Myasthenia Gravis).subjects at potentially high risk for pneumonia (e.g. very low BMI, severely malnourished, or very low FEV1) will only be included at the discretion of the investigator.
• Pneumonia and/or moderate or severe COPD exacerbation that has not resolved at least 14 days prior to Screening (V1) and at least 30 days following the last dose of oral/systemic corticosteroids (if applicable).
• Other respiratory tract infections that have not resolved at least 7 days prior to Screening (V1).
• Chest x-ray reveals evidence of pneumonia or a clinically significant abnormality not believed to be due to the presence of COPD, or another condition that would hinder the ability to detect an infiltrate on chest x-ray (e.g. significant cardiomegaly, pleural effusion or scarring). All subjects will have a chest x-ray at Screening (V1) \[or historical radiograph or CT scan obtained within 12 months prior to Screening. Subjects who have experienced pneumonia and/or moderate or severe COPD exacerbation within 12 months of Screening (V1) must provide a post pneumonia/exacerbation chest x-ray or have a chest x-ray conducted at Screening (V1)\].
• For sites in Germany: If a chest x-ray (or CT scan) within 12 months prior to Screening (V1) is not available, approval to conduct a diagnostic chest x-ray will need to be obtained from the Federal Office for Radiation Protection (BfS).
• Subjects with historical or current evidence of clinically significant cardiovascular, neurological, psychiatric, renal, hepatic, immunological, gastrointestinal, urogenital, nervous system, musculoskeletal, skin, sensory, endocrine (including uncontrolled diabetes or thyroid disease) or haematological abnormalities that are uncontrolled. Significant is defined as any disease that, in the opinion of the Investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study.
• Alanine aminotransferase (ALT) \>2x upper limit of normal (ULN); and bilirubin \>1.5xULN (isolated bilirubin \>1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35 percent).
• Current active liver or biliary disease (with the exception of Gilbert's syndrome or asymptomatic gallstones or otherwise stable chronic liver disease per investigator assessment).
• Subjects with any of the following at Screening (V1) are excluded:
• Myocardial infarction or unstable angina in the last 6 months

Sponsors & Collaborators

• GlaxoSmithKline: lead

Study Sites (11)

GSK Investigational Site

Truro, Nova Scotia, B2N 1L2, Canada

Location

GSK Investigational Site

Toronto, Ontario, M3J 2C5, Canada

Location

GSK Investigational Site

Toronto, Ontario, M5G 1N8, Canada

Location

GSK Investigational Site

Saint-Charles-Borromée, Quebec, J6E 2B4, Canada

Location

GSK Investigational Site

Geesthacht, Schleswig-Holstein, 21502, Germany

Location

GSK Investigational Site

Berlin, State of Berlin, 10119, Germany

Location

GSK Investigational Site

Berlin, State of Berlin, 10717, Germany

Location

GSK Investigational Site

Berlin, State of Berlin, 10787, Germany

Location

GSK Investigational Site

Berlin, State of Berlin, 12159, Germany

Location

GSK Investigational Site

Berlin, State of Berlin, 12203, Germany

Location

GSK Investigational Site

Berlin, State of Berlin, 13156, Germany

Location

MeSH Terms

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

fluticasone furoate; GSK573719; vilanterol; Albuterol

Condition Hierarchy (Ancestors)

Lung Diseases, Obstructive; Lung Diseases; Respiratory Tract Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Ethanolamines; Amino Alcohols; Alcohols; Organic Chemicals; Amines; Phenethylamines; Ethylamines

Study Officials

• GSK Clinical Trials

  GlaxoSmithKline

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 4, 2016
• First Posted: April 8, 2016
• Study Start: June 1, 2016
• Primary Completion: November 1, 2016
• Study Completion: November 1, 2016
• Last Updated: July 22, 2016

Record last verified: 2016-07

Locations

DE (7); CA (4)